Rewriting the story of vascular health

The appointments add deep expertise in corporate governance, capital markets, and global pharmaceutical leadership at a key stage of Topadur’s development, with TOP-N53 in Phase 2 for systemic sclerosis and TOP-M119 preparing for clinical entry in alopecia.

Topadur Pharma AG announces the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer to lead the next phase of clinical advancement and company growth.

Topadur Pharma AG Secures FDA Orphan Drug Designation for TOP-N53 Targeting Digital Ulcers in Systemic Sclerosis